GlassScriptPhysician profile
Yan Feng
NPI 1003067455
$2,263.04
in general payments reported to CMS, 2019-2025
23 companies · $910 in 2025
The $910 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $77.72 · 2021: $177 · 2022: $50.00 · 2023: $376 · 2024: $297 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,582.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $387.80 | 2019-2025 | Imfinzi, Datroway |
| Beigene USA, INC. | $308.50 | 2022-2024 | Brukinsa |
| Beone Medicines USA, INC. | $252.80 | 2025 | Tevimbra, Brukinsa |
| Tempus Ai, INC | $166.68 | 2025 | Xt Cdx |
| E.R. Squibb & Sons, L.L.C. | $166.28 | 2020-2025 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $163.45 | 2024 | |
| Eisai INC. | $157.10 | 2019-2021 | |
| Incyte Corporation | $125.00 | 2025 | Zynyz |
| Advanced Accelerator Applications | $124.83 | 2019 | |
| Dova Pharmaceuticals | $120.00 | 2019 | |
| Janssen Biotech, INC. | $69.18 | 2020-2023 | Balversa, Erleada |
| Pfizer INC. | $33.21 | 2019-2025 | |
| Amgen INC. | $27.61 | 2020-2023 | Vectibix, Nplate, Xgeva |
| Seagen INC. | $27.13 | 2020-2023 | Tukysa |
| Lilly USA, LLC | $21.91 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.44 | 2019 | |
| Array Biopharma INC | $18.88 | 2025 | Braftovi, Mektovi, Lorbrena |
| Genentech USA, INC. | $18.22 | 2019 | |
| Exelixis INC. | $18.21 | 2025 | Cabometyx |
| Genzyme Corporation | $12.52 | 2021 | |
| Emd Serono, INC. | $12.37 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Feng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.